- The FDA's Gastrointestinal Drugs Advisory Committee votes 17-0 backing approval of Intercept Pharmaceuticals' (ICPT) obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBA), accepting the use of the liver enzyme alkaline phosphatase (ALP) as a surrogate endpoint.
FDA's Ad Comm backs approval of Intercept Pharma's OCA for
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ICPT | - | - |
Intercept Pharmaceuticals, Inc. |